16 September 2021
A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.
23 August 2021
Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.
20 August 2021
The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.
University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships
9 August 2021
Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
9 July 2021
Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
8 July 2021
'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
30 June 2021
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
28 June 2021
The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
28 June 2021
Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
21 June 2021
A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
11 June 2021
Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.
The Oxford-Harrington Rare Disease Centre initiates first disease priority area: Friedreich’s Ataxia
27 May 2021
The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.
COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant
14 May 2021
For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
13 May 2021
Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
6 May 2021
Andrew Pollard writes about vaccine equity in his article for The Conversation.